Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Jeffrey L Seeburger"'
Autor:
Ronald C Hendrickson, Anita Y H Lee, Qinghua Song, Andy Liaw, Matt Wiener, Cloud P Paweletz, Jeffrey L Seeburger, Jenny Li, Fanyu Meng, Ekaterina G Deyanova, Matthew T Mazur, Robert E Settlage, Xuemei Zhao, Katie Southwick, Yi Du, Dan Holder, Jeffrey R Sachs, Omar F Laterza, Aimee Dallob, Derek L Chappell, Karen Snyder, Vijay Modur, Elizabeth King, Catharine Joachim, Andrey Y Bondarenko, Mark Shearman, Keith A Soper, A David Smith, William Z Potter, Ken S Koblan, Alan B Sachs, Nathan A Yates
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0135365 (2015)
Disease modifying treatments for Alzheimer's disease (AD) constitute a major goal in medicine. Current trends suggest that biomarkers reflective of AD neuropathology and modifiable by treatment would provide supportive evidence for disease modificati
Externí odkaz:
https://doaj.org/article/9acb46913f794a2a8b1b2a7a679cc6a4
Autor:
Daniel J. Holder, Jeffrey L. Seeburger, C Joachim, Mary J. Savage, A. David Smith, Marc Combrinck, Vijay Modur, Karen Snyder, William Z. Potter, Michael Tanen, Derek L Chappell, Adam J. Simon, Omar F Laterza, Mary Flynn, Gordon K. Wilcock, Aimee Dallob
Publikováno v:
Journal of Alzheimer's Disease. 44:525-539
Cerebrospinal fluid (CSF) amyloid-β (Aβ) and tau have been studied as markers of Alzheimer's disease (AD). Combined Aβ42 and t-tau distinguishes AD from healthy controls with a sensitivity and specificity (sens/spec) near 89% across studies. This
Autor:
Annika Öhrfelt, Daniel J. Holder, Ulf Andreasson, Adam J. Simon, Viswanath Devanarayan, Henrik Zetterberg, William Z. Potter, Åke Edman, Jeffrey L. Seeburger, A. David Smith, Kaj Blennow, Anders Wallin
Publikováno v:
Dementia and Geriatric Cognitive Disorders EXTRA
Dementia and Geriatric Cognitive Disorders Extra, Vol 1, Iss 1, Pp 31-42 (2011)
Dementia and Geriatric Cognitive Disorders Extra, Vol 1, Iss 1, Pp 31-42 (2011)
Background: Novel biomarkers are important for identifying as well as differentiating subcortical vascular dementia (SVD) and Alzheimer’s disease (AD) at an early stage in the disease process. Methods: In two independent cohorts, a multiplex immuno
Autor:
Deborah I. Friedman, Tony W. Ho, Carolyn M. Hustad, Yang Ge, David J. Hewitt, Lawrence C. Newman, Jeffrey L. Seeburger, Jeanne LaSorda, Frederick R. Taylor, Kathryn M. Connor, Ying Zhang, Xiaoyin Fan
Publikováno v:
Cephalalgia. 31:786-796
Objective: The study was carried out to assess the efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treating acute migraine in patients who are non-responders to sumatriptan. Background: Many migraineurs report dissatis
Autor:
Xuemei Zhao, Jenny J. Li, Yi Du, Jeffrey L. Seeburger, C Joachim, Ronald C. Hendrickson, Andy Liaw, Andrey Bondarenko, Fanyu Meng, Derek L Chappell, Anita Y. H. Lee, Keith A. Soper, William Z. Potter, Mark S. Shearman, Matt Wiener, Nathan A. Yates, Cloud P. Paweletz, Katie Southwick, Qinghua Song, Aimee Dallob, Matthew T. Mazur, Vijay Modur, Robert E. Settlage, E. King, A. David Smith, Omar F Laterza, Ken S. Koblan, Ekaterina G. Deyanova, Karen Snyder, Dan Holder, Jeffrey R. Sachs, Alan B. Sachs
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0135365 (2015)
PLoS ONE
PLoS ONE
Disease modifying treatments for Alzheimer's disease (AD) constitute a major goal in medicine. Current trends suggest that biomarkers reflective of AD neuropathology and modifiable by treatment would provide supportive evidence for disease modificati
Autor:
Eleanor Schaefer, E. Anne MacGregor, Ying Zhang, Dominique Valade, Jeffrey L. Seeburger, Nancy Strickler, Kathryn M. Connor, Yang Ge, Paul Winner, Tony W. Ho, Carolyn M. Hustad, Roger Cady
Publikováno v:
Headache. 52(1)
Objective.— To assess efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treatment of acute migraine in patients using topiramate for migraine prophylaxis. Background.— There are limited data from prospective controll
Publikováno v:
Brain Research. 621:111-115
In the present study, in situ hybridization was used to examine the expression of nerve growth factor (NGF) receptor (p75NGFR), trk (p140trk) and trkB (p145trkB) mRNA in spinal cord sections from patients with amyotrophic lateral sclerosis (ALS). We
Autor:
Matt Wiener, Anita Lee, Qinghua Song, Mark S. Shearman, Andy Liaw, Catherine Joachim, Cloud P. Paweletz, Jenny J. Li, Xuemei Zhao, Vijay Modur, Matthew T. Mazur, Ken S. Koblan, David Smith, Jeffrey L. Seeburger, Robert E. Settlage, Fanyu Meng, Ronald C. Hendrickson, Ekaterina G. Deyanova, E. King, William Z. Potter, Keith A. Soper, Jeffrey R. Sachs, Nathan A. Yates
Publikováno v:
Alzheimer's & Dementia. 6
Autor:
Jonathan H Williams, Jeffrey L. Seeburger, A. David Smith, Aimee Dallob, William Z. Potter, Omar F Laterza, Gordon K. Wilcock
Publikováno v:
Alzheimer's Research & Therapy
INTRODUCTION: Levels of cerebrospinal fluid (CSF) β-amyloid (Aβ) and Tau proteins change in Alzheimer's disease (AD). We tested if the relationships of these biomarkers with cognitive impairment are linear or non-linear. METHODS: We assessed cognit
Autor:
David S. Miller, J. Michael Ryan, Daniel Saumier, Ronald Black, Jeffrey L. Seeburger, Barry D. Greenberg, Joan Amatniek, Yaakov Stern, Richard C. Mohs, Malca Resnick, Holly Posner, Maria C. Carrillo
Publikováno v:
Alzheimer'sdementia : the journal of the Alzheimer's Association. 5(4)
The assessment of patient outcomes in clinical trials of new therapeutics for Alzheimer's disease (AD) continues to evolve. In addition to assessing drugs for symptomatic relief, an increasing number of trials are focusing on potential disease-modify